argenx NV ADR vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

argenx NV ADR (ARGX)

Q3 202623 Jul – 29 Jul 2026

▲2

argenx beats on strong sales, buys Forte to expand pipeline

Q2 earnings beat with 60% sales growth argenx reported Q2 GAAP EPS of $7.32, beating estimates by $1.12, with revenue up 60% to $1.52 billion. Cash flow turned positive and cash rose to $5.2 billion. This shows the core business is growing fast and generating cash, which supports a higher stock price.
This is the main new financial result that directly shows the company's strong performance and supports the stock.
VYVGART label expanded and pipeline milestones ahead argenx launched an expanded U.S. label for VYVGART covering all serotypes of generalized myasthenia gravis. It also expects key trial results in autoimmune myositis and multifocal motor neuropathy later this year. These could open new markets and drive future sales growth.
This points to future growth drivers beyond the current quarter, which investors care about for the long-term story.
Acquiring Forte Biosciences for $2.2 billion in cash argenx agreed to buy Forte Biosciences for $77 per share, or about $2.2 billion in cash, adding a first-in-class antibody for vitiligo and celiac disease. The deal uses cash reserves but could strengthen the pipeline. The stock may react to the cost versus the potential new treatment.
This is a major strategic move that affects the company's cash and future pipeline, directly influencing the investment case.

July 202623 Jul – 29 Jul 2026

▲2

argenx beats on strong sales, buys Forte to expand pipeline

Q2 earnings beat with 60% sales growth argenx reported Q2 GAAP EPS of $7.32, beating estimates by $1.12, with revenue up 60% to $1.52 billion. Cash flow turned positive and cash rose to $5.2 billion. This shows the core business is growing fast and generating cash, which supports a higher stock price.
This is the main new financial result that directly shows the company's strong performance and supports the stock.
VYVGART label expanded and pipeline milestones ahead argenx launched an expanded U.S. label for VYVGART covering all serotypes of generalized myasthenia gravis. It also expects key trial results in autoimmune myositis and multifocal motor neuropathy later this year. These could open new markets and drive future sales growth.
This points to future growth drivers beyond the current quarter, which investors care about for the long-term story.
Acquiring Forte Biosciences for $2.2 billion in cash argenx agreed to buy Forte Biosciences for $77 per share, or about $2.2 billion in cash, adding a first-in-class antibody for vitiligo and celiac disease. The deal uses cash reserves but could strengthen the pipeline. The stock may react to the cost versus the potential new treatment.
This is a major strategic move that affects the company's cash and future pipeline, directly influencing the investment case.

Latest23 Jul – 29 Jul 2026

▲2

argenx beats on strong sales, buys Forte to expand pipeline

Q2 earnings beat with 60% sales growth argenx reported Q2 GAAP EPS of $7.32, beating estimates by $1.12, with revenue up 60% to $1.52 billion. Cash flow turned positive and cash rose to $5.2 billion. This shows the core business is growing fast and generating cash, which supports a higher stock price.
This is the main new financial result that directly shows the company's strong performance and supports the stock.
VYVGART label expanded and pipeline milestones ahead argenx launched an expanded U.S. label for VYVGART covering all serotypes of generalized myasthenia gravis. It also expects key trial results in autoimmune myositis and multifocal motor neuropathy later this year. These could open new markets and drive future sales growth.
This points to future growth drivers beyond the current quarter, which investors care about for the long-term story.
Acquiring Forte Biosciences for $2.2 billion in cash argenx agreed to buy Forte Biosciences for $77 per share, or about $2.2 billion in cash, adding a first-in-class antibody for vitiligo and celiac disease. The deal uses cash reserves but could strengthen the pipeline. The stock may react to the cost versus the potential new treatment.
This is a major strategic move that affects the company's cash and future pipeline, directly influencing the investment case.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.